Mainz Biomed N.V.
QUCY evidence brief
What we can confirm
- BioSniper Score:
- 5.0 / 10
- Market Cap:
- $116.0M
- Lead Asset:
- pancalert (Preclinical)
What it means
What to watch
Prepared research question
What matters most for QUCY—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · QUCY
Mainz Biomed N.V. is a biotech company that pivoted from colorectal cancer screening to focus on pancreatic cancer screening, having sold its ColoAlert and NextGen assets and undergone leadership changes in early 2026.
Key risk: Net loss and cash burn
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Market Cap
$116.0M
Cash Runway
—
Lead Asset
pancalert (Preclinical)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate · 1 clinical trial for Mainz Biomed N.V..
Mainz Biomed N.V. is a biotech company that pivoted from colorectal cancer screening to focus on pancreatic cancer screening, having sold its ColoAlert and NextGen assets and undergone leadership changes in early 2026.
- Cash & equivalents of $13.4M as of 2026-06-30 [sec]
- Net income of -$11.0M as of 2026-06-30 [sec]
- Shareholders' equity of $20.4M as of 2026-06-30 [sec]
- In February 2026, the Board decided to close the colorectal cancer line of business to focus on the pancreatic screening line of business [sec_mda · as of 2026-08-14]
- On March 28, 2026, the Company closed the sale of ColoAlert assets to UTR for $348,966, reducing a debt of $648,966 [sec_mda · as of 2026-05-15]
What works
- The company has a focused strategy on pancreatic cancer screening after divesting colorectal assets, which may allow concentration of resources [sec_mda · as of 2026-08-14]
- New leadership was appointed in March 2026, including Robert Liscouski as non-executive Chairman and David Lazar as director and CEO, to align strategy with the pancreatic focus [sec_mda · as of 2026-08-14]
- The company raised capital through a private placement of preferred shares in early 2026, with a second closing completed on April 22, 2026 [sec_mda · as of 2026-08-14]
What to weigh
- The company reported a net loss of $11.0M as of 2026-06-30 [sec]
- The company terminated all employees in its German subsidiary between February and May 2026 as part of the strategic pivot [sec_mda · as of 2026-05-15]
- The sale of ColoAlert assets resulted in a net payment of $300,000 to UTR, indicating the assets were sold at a discount relative to the debt [sec_mda · as of 2026-05-15]
From the filings
Quoted directly from source documents.
Strategic pivot to pancreatic cancer screening
“Directors made the decision to close our colorectal cancer line of business to focus on the pancreatic screening line of business.”
SEC MD&A · August 14, 2026
Sale of ColoAlert assets
“On March 28, 2026 the Company closed the sale of the ColoAlert assets to UTR, which included the ColoAlert intellectual property, customer-located instrumentation, and certain consumables, and included the transfer of two equipment lease obligations. The purchase price for the assets was $348,966, which reduced the debt owed to UTR of $648,966, resulting in a net payment to UTR of $300,000 at closing.”
SEC MD&A · May 15, 2026
Leadership changes
“In March 2026, the Company announced the appointment of Robert Liscouski as its non-executive Chairman, with David Lazar assuming the position of director and CEO.”
SEC MD&A · August 14, 2026
Risks & what to watch (3)›
Key risks
- Net loss and cash burn — Net loss of $11.0M as of 2026-06-30 with cash of $13.4M, indicating limited runway [sec]
- Strategic pivot execution — Company sold core colorectal assets and terminated German employees, now dependent on unproven pancreatic screening line [sec_mda · as of 2026-08-14]
- Competitive pancreatic cancer landscape — Multiple competitors are running pancreatic cancer trials (e.g., Beijing Gene Key, Guangzhou JOYO Pharma) [competitor_trial]
What to watch
- Progress and clinical milestones in the pancreatic cancer screening line of business [sec_mda · as of 2026-08-14]
- Cash runway and ability to raise additional capital given $13.4M cash and $11.0M net loss as of 2026-06-30 [sec]
- Integration and effectiveness of new leadership under Robert Liscouski and David Lazar [sec_mda · as of 2026-08-14]
Sources: Competitor trials · SEC MD&A · Generated October 7, 2026 · How we verify sources →
Run Mainz Biomed N.V. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Mainz Biomed N.V. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.15 · 0% dilution
Lead: Preclinical
1 candidate
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Regulatory
Financials
Short Interest
as of May 22, 2026- % of float
- 8.5%
- Days to cover
- 0.8
- Shares short
- 960,587
- Daily short volume (May 8, 2026)
- 53.6%
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
QUCY short interestGovernance
Frequently asked questions
What is the AI investment thesis for Mainz Biomed N.V.?
Mainz Biomed N.V. is a biotech company that pivoted from colorectal cancer screening to focus on pancreatic cancer screening, having sold its ColoAlert and NextGen assets and undergone leadership changes in early 2026.
What is Mainz Biomed N.V.'s lead drug candidate?
Mainz Biomed N.V.'s most advanced tracked candidate is pancalert (Preclinical) for Pancreatic cancer.
Who is the CEO of Mainz Biomed N.V.?
Mr. David Elliot Lazar is the chief executive officer of Mainz Biomed N.V. (QUCY).
Where is Mainz Biomed N.V. headquartered?
Mainz Biomed N.V. (QUCY) is headquartered in Mainz, Germany.
What therapeutic areas does Mainz Biomed N.V. focus on?
Mainz Biomed N.V. develops therapies across Oncology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.